gyrA mutations fluoroquinoloneresistant Clostridium difficile PCR-027 [3]

Emerging Infectious Diseases

Volumn 13, Issue 3, 2007, Pages 504-505

  Drudy, Denise ^a   Kyne, Lorraine ^b   O'Mahony, Rebecca ^a   Fanning, Séamus ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; LETTER; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RIBOTYPING; CLASSIFICATION; COMMUNICABLE DISEASE; DRUG EFFECT; GENETICS; HUMAN; IRELAND; MICROBIOLOGY; MUTATION; SPECIES DIFFERENCE;

AMINO ACID SUBSTITUTION; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNICABLE DISEASES, EMERGING; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; IRELAND; MUTATION; SPECIES SPECIFICITY;

EID: 33847416012     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1303.060771     Document Type: Letter

References (10)

1. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30:753-77.
2. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004;38:646-8.
3. Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999;341:1645-51.
4. Kuijper EJ, Coignard B, Tull P. the ESCMID Study Group for Clostridium difficile (ESGCD), EU Member States and the European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile- associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2-18.
5. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-84.
6. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat. 1999;2:38-55.
7. Ackermann G, Tang YJ, Kueper R, Heisig P, Rodloff AC, Silva J Jr, et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother. 2001;45:2348-53.
8. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002;46:3418-21.
9. Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother. 2006;58:1264-7.
10. Wilcox MH, Fawley W, Freeman J, Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother. 2000;46:551-6.